NR4A1 and aneurysmal bone cyst: While cyclin‐dependent kinase 4/6 inhibitors (CDKIs) combined with endocrine therapy (ET) delay resistance in hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative ABC, their impact on CNS metastasis development has not been fully elucidated.